Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

September 30, 2018

Conditions
Solid Tumor
Interventions
DRUG

C-14 labeled Rucaparib

Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib

DRUG

Rucaparib

200 \& 300 mg tablet

Trial Locations (1)

1077

PRA Magyarország Kft., Budapest

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT02986100 - Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | Biotech Hunter | Biotech Hunter